• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Neurology

Ocrelizumab associated with lower progression rates for primary progressive multiple sclerosis: The ORATORIO trial

byDavid ArsaniousandShaidah Deghan, MSc. MD
January 19, 2017
in Neurology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. A significant decrease in the rate of clinical and MRI progression was observed for Primary progressive multiple sclerosis (PPMS) patients that received ocrelizumab.

2. Rates of infections, infusion-related reactions, and neoplasms were higher in PPMS patients who received ocrelizumab, although there was a nonsignificant decrease in serious adverse events in patients who received ocrelizumab.

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Primary progressive multiple sclerosis (PPMS) is a form of multiple sclerosis characterized by progressive neurologic decline that begins at the onset of symptoms. As B cells have been implicated in the pathogenesis of PPMS, this study investigated the efficacy and safety of the anti-CD20 monoclonal antibody ocrelizumab in patients with PPMS.

The rates of clinical progression at 12, 24, and 120 weeks were significantly lower in patients who received ocrelizumab compared to placebo at all three time points. There were significant reductions in the progression of T2-hyperintensities and loss of brain volume on MRI at 120 weeks in patients who received ocrelizumab versus placebo. The rates of any adverse event, serious adverse events, adverse events that led to discontinuation of the trial agent, death, infusion-related reactions, serious infections, and neoplasm were higher in patients who received ocrelizumab, although the rates of serious adverse events did not differ significantly between groups.

Click to read the study, published today in NEJM

RELATED REPORTS

Tolebrutinib not superior to teriflunomide in reducing relapsing multiple sclerosis relapse rates

Tolebrutinib reduces disability progression in nonrelapsing secondary progressive multiple sclerosis

#VisualAbstract: Tolebrutinib Reduced Disaibility Progression in Nonrelapsing Secondary Progressive Multiple Sclerosis

Relevant Reading: B cell immunobiology in disease: evolving concepts from the clinic

In-Depth [randomized controlled trial]: The ORATORIO study was a phase 3, multi-centre, randomized, parallel-group, double-blind, placebo-controlled, trial. At 12 weeks, disability progression was confirmed in 32.9% of patients in the ocrelizumab group versus 39.3% of patients who received placebo (HR 0.76; 95%CI 0.58 to 0.98; p = 0.03). At 24 weeks, disability progression was confirmed in 29.6% of patients in the ocrelizumab group compared to 35.7% of patients who received placebo (HR 0.75; 95%CI 0.59 to 0.98; p = 0.04). At 120 weeks, worsened performance on the timed 25-foot walk was observed in 38.9% of patients in the ocrelizumab group compared to 55.1% of patients who received placebo (p = 0.04). Between 0 and 120 weeks, the volume of T2 hyperintensities decreased by 3.4% in the ocrelizumab group and increased by 7.4% in patients who received placebo (p < 0.001). Between 24 and 120 weeks, brain volume loss was 0.90% in patients in the ocrelizumab group versus 1.09% in patients who received placebo (p = 0.02). The proportion of patients who had ≥1 infusion-related reaction was 39.9% in patients who received ocrelizumab and 25.5% in patients who received placebo. The proportion of patients who had any serious adverse event was 20.4% in patients who received ocrelizumab and 22.2% of patients who received placebo. The proportion of patients who had serious infections was 6.2% in patients who received ocrelizumab and 5.9% in patients who received placebo. The proportion of patients who developed neoplasms was 2.3% in patients who received ocrelizumab and 0.8% in patients who received placebo.

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: multiple sclerosis
Previous Post

Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities

Next Post

Ocrelizumab decreases multiple sclerosis relapse rate compared to interferon beta-1a

RelatedReports

Chronic Disease

Tolebrutinib not superior to teriflunomide in reducing relapsing multiple sclerosis relapse rates

June 2, 2025
Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities
Chronic Disease

Tolebrutinib reduces disability progression in nonrelapsing secondary progressive multiple sclerosis

June 5, 2025
#VisualAbstract: Tolebrutinib Reduced Disaibility Progression in Nonrelapsing Secondary Progressive Multiple Sclerosis
StudyGraphics

#VisualAbstract: Tolebrutinib Reduced Disaibility Progression in Nonrelapsing Secondary Progressive Multiple Sclerosis

May 30, 2025
#VisualAbstract: Tolebrutinib is Not Superior to Teriflunomide in the Treatment of Relapsing Multiple Sclerosis
StudyGraphics

#VisualAbstract: Tolebrutinib is Not Superior to Teriflunomide in the Treatment of Relapsing Multiple Sclerosis

April 21, 2025
Next Post
Brain lesions on MRI linked with subsequent increased stroke risk

Ocrelizumab decreases multiple sclerosis relapse rate compared to interferon beta-1a

Intrapartum serum prolactin may predict risk of postpartum diabetes

Diabetes linked to increased mortality in China

AAP reaffirms support for adolescents’ rights to confidential reproductive care

AAP reaffirms support for adolescents’ rights to confidential reproductive care

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
  • Evaluating scar outcomes in pediatric burn patients following skin grafting 
  • Novel inhibitory antibody, MAR001, lowers triglycerides and remnant cholesterol in humans
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.